文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

阿基仑赛作为大B细胞淋巴瘤二线治疗

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
PubMed 文献 · N Engl J Med · 2021-12-11

这项国际3期试验将180例对一线化学免疫治疗难治或12个月内复发的大B细胞淋巴瘤患者随机分配至阿基仑赛组和标准治疗组。中位随访24.9个月时,阿基仑赛组中位无事件生存期为8.3个月,标准治疗组为2.0个月(风险比0.40;95%CI 0.31-0.51;P<0.001)。阿基仑赛组缓解率83%,标准治疗组50%;3级及以上不良事件发生率分别为91%和83%。

要点

  • 阿基仑赛显著改善无事件生存期:中位8.3个月 vs 2.0个月,24个月无事件生存率41% vs 16%。
  • 缓解率:阿基仑赛组83%(完全缓解65%),标准治疗组50%(完全缓解32%)。
  • 3级及以上细胞因子释放综合征发生率6%,3级及以上神经系统事件发生率21%。

核心结论

  • 与标准治疗相比,阿基仑赛治疗显著改善无事件生存期和缓解率,并伴有预期水平的高级别毒性作用。

研究设计与样本

  • 国际、3期随机对照试验,按1:1比例将患者随机分配至阿基仑赛组或标准治疗组。
  • 纳入对一线化学免疫治疗难治或12个月内复发的大B细胞淋巴瘤患者,共180例接受阿基仑赛,179例接受标准治疗。

主要发现

  • 中位随访24.9个月时,阿基仑赛组中位无事件生存期为8.3个月,标准治疗组为2.0个月(风险比0.40;95%CI 0.31-0.51;P<0.001)。
  • 24个月无事件生存率:阿基仑赛组41%,标准治疗组16%。
  • 缓解率:阿基仑赛组83%,标准治疗组50%(完全缓解率分别为65%和32%)。
  • 2年总生存率估计值:阿基仑赛组61%,标准治疗组52%(中期分析)。
  • 3级及以上不良事件发生率:阿基仑赛组91%,标准治疗组83%。

关键数值与推荐

  • 阿基仑赛组3级及以上细胞因子释放综合征发生率为6%,3级及以上神经系统事件发生率为21%。
  • 未发生与细胞因子释放综合征或神经系统事件相关的死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoimmunotherapy is poor. METHODS: In this international, phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with large B-cell lymphoma that was refractory to or had relapsed no more than 12 months after first-line chemoimmunotherapy to receive axicabtagene ciloleucel (axi-cel, an autologous anti-CD19 chimeric antigen receptor T-cell therapy) or standard care (two or three cycles of investigator-selected, protocol-defined chemoimmunotherapy, followed by high-dose chemotherapy with autologous stem-cell transplantation in patients with a response to the chemoimmunotherapy). The primary end point was event-free survival according to blinded central review. Key secondary end points were response and overall survival. Safety was also assessed. RESULTS: A total of 180 patients were randomly assigned to receive axi-cel and 179 to receive standard care. The primary end-point analysis of event-free survival showed that axi-cel therapy was superior to standard care. At a median follow-up of 24.9 months, the median event-free survival was 8.3 months in the axi-cel group and 2.0 months in the standard-care group, and the 24-month event-free survival was 41% and 16%, respectively (hazard ratio for event or death, 0.40; 95% confidence interval, 0.31 to 0.51; P<0.001). A response occurred in 83% of the patients in the axi-cel group and in 50% of those in the standard-care group (with a complete response in 65% and 32%, respectively). In an interim analysis, the estimated overall survival at 2 years was 61% in the axi-cel group and 52% in the standard-care group. Adverse events of grade 3 or higher occurred in 91% of the patients who received axi-cel and in 83% of those who received standard care. Among patients who received axi-cel, grade 3 or higher cytokine release syndrome occurred in 6% and grade 3 or higher neurologic events in 21%. No deaths related to cytokine release syndrome or neurologic events occurred. CONCLUSIONS: Axi-cel therapy led to significant improvements, as compared with standard care, in event-free survival and response, with the expected level of high-grade toxic effects. (Funded by Kite; ZUMA-7 ClinicalTrials.gov number, NCT03391466.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2021. PMID: 34891224. doi:10.1056/NEJMoa2116133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。